African Americans experience longer delay between prostate cancer diagnosis and treatment

African American men on average wait a week longer than their Caucasian counterparts between the initial diagnosis of prostate cancer and treatment, according to a new study. The study is the first population-based examination of racial disparities in prostate cancer treatment delay that has been published.

Using data from Medicare patients, the treatment of 2,506 African American and 21,454 Caucasian patients with a diagnosis of early prostate cancer from 2004 to 2007 was compared. The data showed that, on average, African Americans experienced a 7-day longer delay in treatment.

"These are all patients with some form of insurance, ie, Medicare, so it is not a lack of insurance that delays the care," said Ronald Chen, MD, MPH, Assistant Professor with the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill.

Multiple prior studies have found that the disparity in survival rates between African American and Caucasians with prostate cancer is the highest of any malignancy, and African American men are 2.4 times more likely to die from the disease. Prostate cancer is the most common cancer among all American men, with more than 240,000 diagnoses per year. It ranks as the second leading cause of cancer death among men, killing more than 28,000 annually.

The treatment delay was more pronounced among patients who were diagnosed with aggressive, high-risk, prostate cancer, where African American patients experienced a 9-day longer delay than Caucasians. The study was published online in Cancer, the journal of the American Cancer Society.

"Other studies have shown that African American men are less likely to get screened, they get diagnosed with more advanced cancers, and they are less likely to get aggressive treatment when they are diagnosed. Now we have shown that African American patients also wait longer for treatment. I think all of these disparities together add up to contribute to  worse long-term survival outcomes for African American patients," said Chen.

While the data did not reveal the impact of the delay on patient survival, Chen noted that the Institute of Medicine has identified timely delivery of care as an important indicator of the quality of that care. To determine the reasons behind the delay, further studies will need to focus on the personal and institutional factors that lead to the disparities in treatment.

"What our study does is that it identifies an area of need, an area of disparity. More studies are needed to figure out why and to find ways to address disparities in care," said Chen.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs